Compare Dolby Laboratories, Inc. (DLB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs TG Therapeutics Inc — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.75B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLB | TGTX | |
|---|---|---|
Market Cap | $5.75B | $7.64B |
Sector | Industrials | Health |
52-Week High | $75.62 | $59.06 |
52-Week Low | $48.51 | $26.94 |
Enterprise Value | $5.12B | $7.84B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $61.39, down 1.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50. The company has beaten EPS estimates for the last four quarters, including Q2 2026, and maintains strong profitability with an 87.61% gross margin. Recent news highlights growth in Dolby Atmos and auto licensing, though revenue declined year-over-year in Q3 2026.
The outlook is positive with analyst support and operational strength, but risks include licensing volatility and near-term execution challenges. The stock offers upside to the price target, supported by cash flow growth and market expansion in audio-visual technologies.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
